{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T21:58:21Z","timestamp":1787695101288,"version":"build-2784847793"},"reference-count":28,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,5,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Multiple myeloma (MM) is a plasma cell malignancy that is characterized by diverse clinical presentations. Although biochemical assessment of disease activity is commonly used to monitor treatment response, findings on magnetic resonance imaging and positron emission tomography (PET)\/computed tomography (CT), among other imaging modalities, have proven to harbor prognostic value. We sought to corroborate these findings by examining the prognostic significance of fluorodeoxyglucose PET\/CT scanning in the setting of newly diagnosed MM. We retrospectively analyzed 195 patients with a PET\/CT available at diagnosis and at 6 months posttreatment to examine their value as an adjuvant metric to conventional hematologic responses in terms of time to next treatment (TTNT) and overall survival (OS). The median TTNT and OS for the entire cohort were 24.6 months (95% confidence interval [CI], 20.4-29.1) and 79 months (95% CI, 63.1-119.1), respectively. When comparing PET\/CT negative (\u2212) with PET\/CT positive (+) patients, we found significantly prolonged median TTNT (55.2 vs 17.8 months, P &amp;lt; .0001) and OS (unreached vs 60.8 months, P &amp;lt; .0001) in the former group. We then examined the additive value of PET\/CT on the hematologic response achieved at 6 months and found that PET\/CT (\u2212) is associated with significantly increased median TTNT and OS for the very good partial response (VGPR) group and the less than VGPR group. Importantly, PET\/CT retained prognostic significance after adjusting for multiple other predictive variables. We conclude that a PET\/CT (\u2212) at 6 months confers a significant prognostic advantage for patients with newly diagnosed MM and adds significant value to the hematologic response assessment.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022007052","type":"journal-article","created":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T22:21:34Z","timestamp":1646259694000},"page":"2763-2772","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":28,"title":["Utility of PET\/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma"],"prefix":"10.1182","volume":"6","author":[{"given":"Charalampos","family":"Charalampous","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1663-0325","authenticated-orcid":false,"given":"Utkarsh","family":"Goel","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5391-9537","authenticated-orcid":false,"given":"Stephen M.","family":"Broski","sequence":"additional","affiliation":[{"name":"Department of Radiology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dingli","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3853-5196","authenticated-orcid":false,"given":"Morie A.","family":"Gertz","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1193-1559","authenticated-orcid":false,"given":"Martha Q.","family":"Lacy","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8780-9512","authenticated-orcid":false,"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne R.","family":"Hayman","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3214-0203","authenticated-orcid":false,"given":"Francis","family":"Buadi","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Hwa","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5651-1411","authenticated-orcid":false,"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson I.","family":"Gonsalves","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8573-9434","authenticated-orcid":false,"given":"Taxiarchis V.","family":"Kourelis","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0240-0326","authenticated-orcid":false,"given":"Rahma","family":"Warsame","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9488-8212","authenticated-orcid":false,"given":"Amie","family":"Fonder","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Hobbs","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9014-9658","authenticated-orcid":false,"given":"Moritz","family":"Binder","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Kyle","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji K.","family":"Kumar","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,4,29]]},"reference":[{"issue":"15","key":"2022042915222826100_B1","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1182\/blood-2009-03-201053","article-title":"The role of complete response in multiple myeloma","volume":"114","author":"Harousseau","year":"2009","journal-title":"Blood."},{"issue":"1","key":"2022042915222826100_B2","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41467-017-00296-y","article-title":"Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing","volume":"8","author":"Rasche","year":"2017","journal-title":"Nat Commun."},{"issue":"7","key":"2022042915222826100_B3","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41571-018-0018-y","article-title":"The multiple myelomas: current concepts in cytogenetic classification and therapy","volume":"15","author":"Kumar","year":"2018","journal-title":"Nat Rev Clin Oncol."},{"issue":"6","key":"2022042915222826100_B4","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00277-020-03984-w","article-title":"Clinical characteristics and outcomes of oligosecretory and non-secretory multiple myeloma","volume":"99","author":"Migkou","year":"2020","journal-title":"Ann Hematol."},{"issue":"8","key":"2022042915222826100_B5","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"2022042915222826100_B6","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.blre.2019.04.002","article-title":"Extramedullary disease in multiple myeloma - controversies and future directions","volume":"36","author":"Sevcikova","year":"2019","journal-title":"Blood Rev."},{"issue":"21","key":"2022042915222826100_B7","first-page":"3141","article-title":"Incidence and survival outcomes of extramedullary myeloma","volume":"122","author":"Ghimire","year":"2013","journal-title":"Blood."},{"issue":"4","key":"2022042915222826100_B8","doi-asserted-by":"crossref","first-page":"980","DOI":"10.2214\/AJR.08.1633","article-title":"Whole-Body MRI versus PET in assessment of multiple myeloma disease activity","volume":"192","author":"Shortt","year":"2009","journal-title":"AJR Am J Roentgenol."},{"issue":"6","key":"2022042915222826100_B9","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s11604-018-0738-z","article-title":"Diagnostic performance of 18F-FDG PET\/CT and whole-body MRI before and early after treatment of multiple myeloma: a prospective comparative study","volume":"36","author":"Basha","year":"2018","journal-title":"Jpn J Radiol."},{"issue":"2","key":"2022042915222826100_B10","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1148\/rg.352140112","article-title":"MR imaging and PET\/CT in diagnosis and management of multiple myeloma","volume":"35","author":"Ferraro","year":"2015","journal-title":"Radiographics."},{"issue":"1","key":"2022042915222826100_B11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00256-021-03771-2","article-title":"Role of FDG PET in the staging of multiple myeloma","volume":"51","author":"Vicentini","year":"2022","journal-title":"Skeletal Radiol."},{"issue":"19","key":"2022042915222826100_B12","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1158\/1078-0432.CCR-15-0396","article-title":"PET\/CT improves the definition of complete response and allows to detect otherwise unidentifiable skeletal progression in multiple myeloma","volume":"21","author":"Zamagni","year":"2015","journal-title":"Clin Cancer Res."},{"issue":"3","key":"2022042915222826100_B13","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.cpet.2019.03.005","article-title":"Fluorodeoxyglucose-PET\/computed tomography as a predictor of prognosis in multiple myeloma","volume":"14","author":"Nanni","year":"2019","journal-title":"PET Clin."},{"issue":"10","key":"2022042915222826100_B14","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1182\/blood-2012-08-451690","article-title":"Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3","volume":"121","author":"Usmani","year":"2013","journal-title":"Blood."},{"issue":"6","key":"2022042915222826100_B15","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3324\/haematol.2017.177139","article-title":"Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma","volume":"103","author":"Davies","year":"2018","journal-title":"Haematologica."},{"issue":"13","key":"2022042915222826100_B16","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/bloodadvances.2020004131","article-title":"Prognostic impact of posttransplant FDG PET\/CT scan in multiple myeloma","volume":"5","author":"Kaddoura","year":"2021","journal-title":"Blood Adv."},{"issue":"6","key":"2022042915222826100_B17","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.bbmt.2015.03.001","article-title":"The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation","volume":"21","author":"Patriarca","year":"2015","journal-title":"Biol Blood Marrow Transplant."},{"issue":"10","key":"2022042915222826100_B18","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","article-title":"F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma","volume":"114","author":"Bartel","year":"2009","journal-title":"Blood."},{"issue":"2","key":"2022042915222826100_B19","doi-asserted-by":"crossref","first-page":"e530","DOI":"10.1038\/bcj.2017.14","article-title":"Discrepancies between the percentage of plasma cells in bone marrow aspiration and BM biopsy: impact on the revised IMWG diagnostic criteria of multiple myeloma","volume":"7","author":"Lee","year":"2017","journal-title":"Blood Cancer J."},{"issue":"2","key":"2022042915222826100_B20","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1097\/RLU.0b013e318266cee2","article-title":"The value of 18F-FDG PET\/CT after autologous stem cell transplantation (ASCT) in patients affected by multiple myeloma (MM): experience with 77 patients","volume":"38","author":"Nanni","year":"2013","journal-title":"Clin Nucl Med."},{"issue":"23","key":"2022042915222826100_B21","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1182\/blood.V126.23.395.395","article-title":"Prospective evaluation of MRI and PET-CT at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM\/DFCI 2009 Trial","volume":"126","author":"Moreau","year":"2015","journal-title":"Blood."},{"issue":"4","key":"2022042915222826100_B22","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","article-title":"Role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group","volume":"18","author":"Cavo","year":"2017","journal-title":"Lancet Oncol."},{"issue":"1","key":"2022042915222826100_B23","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2017-03-774422","article-title":"Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma","volume":"130","author":"Rasche","year":"2017","journal-title":"Blood."},{"issue":"2","key":"2022042915222826100_B24","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1200\/JCO.20.00386","article-title":"Standardization of 18F-FDG-PET\/CT according to Deauville criteria for metabolic complete response definition in newly diagnosed multiple myeloma","volume":"39","author":"Zamagni","year":"2021","journal-title":"J Clin Oncol."},{"issue":"5","key":"2022042915222826100_B25","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1007\/s00259-017-3909-8","article-title":"Interpretation criteria for FDG PET\/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe)","volume":"45","author":"Nanni","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"23","key":"2022042915222826100_B26","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","article-title":"Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation","volume":"118","author":"Zamagni","year":"2011","journal-title":"Blood."},{"issue":"2","key":"2022042915222826100_B27","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/annonc\/mdp329","article-title":"Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients","volume":"21","author":"Varettoni","year":"2010","journal-title":"Ann Oncol."},{"issue":"3","key":"2022042915222826100_B28","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/s41375-021-01453-5","article-title":"Mortality trends in multiple myeloma after the introduction of novel therapies in the United States","volume":"36","author":"Binder","year":"2022","journal-title":"Leukemia."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/9\/2763\/1894257\/advancesadv2022007052.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/9\/2763\/1894257\/advancesadv2022007052.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T23:44:27Z","timestamp":1651275867000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/9\/2763\/484230\/Utility-of-PET-CT-in-assessing-early-treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,29]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,5,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007052","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,29]]}}}